CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and ...

Summary

CASI Pharmaceuticals, a biopharmaceutical company based in Beijing, China, reported lower 2023 revenue for EVOMELA® and expanded its commercial product portfolio with FOLOTYN® in China for PTCL. Their strategic focus remained on pipeline development, with milestones achieved for CAR T cell therapy and treatments for multiple myeloma and other conditions. Key product and financial updates reflect CASI's navigation through market challenges and advancement of their biopharma portfolio.